|
PARKINSON DISEASE, LATE-ONSET
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Sporadic Parkinson's disease (PD) patients have lower α-galactosidase A (α-GAL A) enzymatic activity and Fabry disease (FD) patients potentially carry an increased risk of PD.
|
31594250 |
2020 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
The results of the present study suggest that BDNF, LXA4, EPA, DHA, AA, GLA and BDNF protect pancreatic β cells from the cytotoxic action of various chemicals and prevent development of diabetes mellitus.
|
31823816 |
2019 |
|
Tuberculosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.
|
31664157 |
2019 |
|
Candidiasis, Vulvovaginal
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess the efficacy of an oral formulation containing Lactobacillus acidophilus GLA-14, Lactobacillus rhamnosus HN001 and bovine lactoferrin on symptoms and recurrence of VVC as adjuvant therapy to topical clotrimazole.
|
30565745 |
2019 |
|
Clinically isolated syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
we evaluated the α-galactosidase A enzymatic activity in 154 patients with a previous diagnosis of MS (93 women and 61 men): 103 Relapsing Remitting MS patients, 19 progressive MS patients and 32 with the clinically isolated syndrome.
|
31715500 |
2019 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Co-administration of HIV-MVA with rgp140/GLA-AF significantly enhanced antibody responses.
|
30496299 |
2018 |
|
Breast Fibrocystic Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Women with FBC using the formula containing GLA, iodine, and selenium experienced reduced nodularity and in those women who took over-the-counter breast pain medication, a decrease in the quantity of pain medication was observed.
|
29237134 |
2018 |
|
Mastodynia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Women with FBC using the formula containing GLA, iodine, and selenium experienced reduced nodularity and in those women who took over-the-counter breast pain medication, a decrease in the quantity of pain medication was observed.
|
29237134 |
2018 |
|
Niemann-Pick Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
To test whether reduction in lysosomal enzymatic activity in PD is specific to GCase, we measured GCase, acid sphingomyelinase (deficient in Niemann-Pick disease types A and B), alpha galactosidase A (deficient in Fabry), acid alpha-glucosidase (deficient in Pompe) and galactosylceramidase (deficient in Krabbe) enzymatic activities in dried blood spots of PD patients (n = 648) and controls (n = 317) recruited from Columbia University.
|
29369793 |
2018 |
|
Priapism
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Fabry disease is a glycosphingolipidosis caused by deficient activity of α-galactosidase A; it is one of a few diseases that are associated with priapism, an abnormal prolonged erection of the penis.
|
29110178 |
2018 |
|
Knee pain
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Results after three months were extracted from the GLA:D database, including a visual analogue scale (VAS) for knee pain 0-100: best-poorest.
|
29886881 |
2018 |
|
Inflammatory pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In turn, GLA KO mice are protected from heat and mechanical hypersensitivity in neuropathic and inflammatory pain models based on reduced neuronal I<sub>h</sub> and Na<sub>v</sub>1.7 currents.
|
30328411 |
2018 |
|
Gastrointestinal symptom
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
In addition to symptomatic treatments, disease-specific enzyme replacement therapy with recombinant human alpha-galactosidase A enzyme or chaperone therapy (migalastat) in patients with amenable mutations can improve the disease, including gastrointestinal symptoms, and should be initiated as early as possible after Fabry disease has been confirmed; starting enzyme replacement therapy at as young an age as possible after diagnosis improves long-term clinical outcomes.
|
29602572 |
2018 |
|
BREAST PAIN FEMALE
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Women with FBC using the formula containing GLA, iodine, and selenium experienced reduced nodularity and in those women who took over-the-counter breast pain medication, a decrease in the quantity of pain medication was observed.
|
29237134 |
2018 |
|
Dissecting aneurysm of the thoracic aorta
|
0.010 |
Biomarker
|
disease |
BEFREE |
GALA was similar in the central locations (55°[49-63], 52°[47-61] and 54°[45-62] from descending thoracic to femoral artery, median[interquartile], p = 0.10), while there was a difference in β angle (16°[4-27] to 8°[3-15], p < 0.0001).
|
29188414 |
2018 |
|
Vascular inflammations
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Signal silencing studies with GGCX siRNA again depicted the role of VK-dependent Gla proteins in mediating the effect of VK1 on vascular inflammation in HG-treated cells.
|
29227493 |
2018 |
|
Acute-On-Chronic Liver Failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this review, we discuss the mechanisms related to the alteration of the GLA and their involvement in ACLF pathogenesis and suggest some possible therapeutic options that could modulate the GLA dysfunction.
|
29200007 |
2018 |
|
IgE-mediated food allergy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Upstream therapies that shift towards a Th1/Treg response include toll-like receptor (TLR) 4 agonists (e.g., MPL and GLA), TLR9 agonists (CpG oligonucleotides), nanoparticles encapsulating peanut allergen (with and without adjuvants, such as CpG or rapamycin), Chinese herbal medicine (food allergy herbal formula (FAHF-2)), probiotics, and interferon-gamma.
|
29968170 |
2018 |
|
Airway Obstruction
|
0.010 |
GeneticVariation
|
group |
BEFREE |
PAI-1 gain-of-function genotype, factors increasing PAI-1 levels, and airway obstruction: The GALA II Cohort.
|
28543872 |
2017 |
|
Asthma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Perceived Discrimination Associated With Asthma and Related Outcomes in Minority Youth: The GALA II and SAGE II Studies.
|
27916618 |
2017 |
|
Primary Erythermalgia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A novel mutation of α-galactosidase A gene causes Fabry disease mimicking primary erythromelalgia in a Chinese family.
|
27211852 |
2017 |
|
Heartburn
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Kassa and GLA 1103 were tolerant to acidity showing less than 3% reduction in taproot length.
|
28194315 |
2017 |
|
Hyperinsulinism
|
0.010 |
Biomarker
|
disease |
BEFREE |
It was uncertain whether an algorithm that involves increasing insulin dosages by 1 unit/day may cause more hypoglycemia with the longer-acting insulin glargine 300 units/mL (GLA-300).
|
28803820 |
2017 |
|
Hypoglycemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
It was uncertain whether an algorithm that involves increasing insulin dosages by 1 unit/day may cause more hypoglycemia with the longer-acting insulin glargine 300 units/mL (GLA-300).
|
28803820 |
2017 |
|
Osteoarthritis of hip
|
0.010 |
Biomarker
|
disease |
BEFREE |
Good Life with osteoArthritis in Denmark (GLA:D) was launched in 2013 with the aim of implementing guidelines for the treatment of knee and hip OA in clinical care nationwide.
|
28173795 |
2017 |